Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS Meeting (II).
For the seventh year in a row the Post-ECTRIMS Meeting has been held in Madrid (Spain). Renowned specialists in multiple sclerosis and national leaders in this area have gathered once again to discuss the novelties presented at the 2014 ECTRIM-ACTRIMS World Congress. That meeting gave rise to this review, which is published in two parts. This second part shows that immunological phenomena are increasingly more present in the pathogenesis of the disease, and that the interaction between inflammation and neurodegeneration is becoming more apparent. Metabolic, mitochondrial dysfunction and oxidative stress phenomena are also involved in axonal degeneration and the experimental models open up the way to promising new therapeutic approaches for regenerative strategies. Although ambitious, inducible neural progenitor cells have become a promising alternative to the conventional treatments with stem cells, and the identification of new genetic variants of susceptibility to multiple sclerosis opens up the way to the discovery of new drugs. Reconsidering the value of old drugs and procedures would be another alternative therapeutic development.
Fundacion IMABIS, Hospital Universitario Carlos Haya, 29190 Malaga, Espana.
O
O
Fernandez
J C
JC
Alvarez-Cermeno
R
R
Arroyo
Ll
L
Brieva
M C
MC
Calles-Hernandez
B
B
Casanova-Estruch
M
M
Comabella
J A
JA
Garcia-Merino
R
R
Ginestal
G
G
Izquierdo
J E
JE
Meca-Lallana
M M
MM
Mendibe-Bilbao
X
X
Montalban
D
D
Munoz-Garcia
J
J
Olascoaga
P
P
Oliva-Nacarino
C
C
Oreja-Guevara
Ll
L
Ramio-Torrenta
L
L
Romero-Pinel
A
A
Rodriguez-Antiguedad
A
A
Saiz
M
M
Tintore
Grupo Post-Ectrims
GP
Grupo Post-Ectrims
D000818:Animals; D000871:Anthelmintics / Q000009:adverse effects / Q000627:therapeutic use; D001323:Autoantibodies / Q000276:immunology; D001369:Axons / Q000276:immunology; D015415:Biomarkers; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004734:Energy Metabolism; D005060:Europe; D005544:Forecasting; D006801:Humans; D016131:Lymphocyte Subsets / Q000276:immunology; D018448:Models, Immunological; D058990:Molecular Targeted Therapy; D009103:Multiple Sclerosis / Q000276:immunology / Q000473:pathology / Q000628:therapy; D058953:Neural Stem Cells / Q000637:transplantation; D059906:Neuroimaging / Q000379:methods; D015213:Neuroimmunomodulation; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010272:Parasitic Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D044968:Regenerative Medicine / Q000379:methods; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D035703:Therapies, Investigational
D000871:Anthelmintics; D001323:Autoantibodies; D015415:Biomarkers; D018696:Neuroprotective Agents